Cargando…
Population pharmacokinetics of tanezumab in phase 3 clinical trials for osteoarthritis pain
AIMS: The aims were to 1) develop the pharmacokinetics model to describe and predict observed tanezumab concentrations over time, 2) test possible covariate parameter relationships that could influence clearance and distribution and 3) assess the impact of fixed dosing vs. a dosing regimen adjusted...
Autores principales: | Jonsson, E. Niclas, Xie, Rujia, Marshall, Scott F., Arends, Rosalin H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4799925/ https://www.ncbi.nlm.nih.gov/pubmed/26613544 http://dx.doi.org/10.1111/bcp.12850 |
Ejemplares similares
-
Population pharmacokinetics of exenatide
por: Cirincione, Brenda, et al.
Publicado: (2016) -
Pharmacokinetics of multiple doses of co‐crystal of tramadol–celecoxib: findings from a four‐way randomized open‐label phase I clinical trial
por: Videla, Sebastián, et al.
Publicado: (2017) -
Single‐dose pharmacokinetics of co‐crystal of tramadol–celecoxib: Results of a four‐way randomized open‐label phase I clinical trial in healthy subjects
por: Videla, Sebastián, et al.
Publicado: (2017) -
Population pharmacokinetic meta‐analysis of ramucirumab in cancer patients
por: O'Brien, Lisa, et al.
Publicado: (2017) -
Safety and efficacy of subcutaneous tanezumab in patients with knee or hip osteoarthritis
por: Birbara, Charles, et al.
Publicado: (2018)